Junsai Biotech Secures ￥100 Million in Series A Funding

(VCBeat) Feb. 26, 2021 -- Recently, Shanghai Junsai Biotechnology Co., Ltd. ("Junsai Biotech"), a company focusing on TIL cellular immunotherapy, announced it has closed ￥100 million in Series A funding. This round of financing was led by Kaitai Capital with participation from Med-Fine Capital and the existing investor Furong Capital. Haoyue Capital served as the exclusive financial adviser for this round.

Established in July 2019 in Shanghai, Junsai Biotech is a global leader in Tumor Infiltrating Lymphocyte (TIL) innovative therapies, dedicated to the development of innovative solid tumor therapies and first-in-class/best-in-class cellular therapy drugs based on TIL, covering a variety of relapsed and refractory tumors.

Junsai Biotech has a professional team in the field of cell therapy. The founder Dr. Jin Huajun has been deeply involved in the research of tumor immunity and cell therapy for more than ten years and has rich experience in the preclinical development and clinical research of TIL therapy. The company has core technologies such as efficient and simple enrichment culture of TIL and efficient and safe nonviral genetic engineering of T cells, with distinct and outstanding advantages in gene&cell therapy.

Kaitai Capital, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc. Currently, the asset under management of Kaitai Capital has reached 50 billion RMB (USD$7.2B).

Founded in 2014 at China's financial hub-Shanghai, Med-Fine Capital is an investment fund. Currently, it manages11 investment funds, of which the amount value has reached nearly 800 million yuan.

Med-Fine Capital mainly invests in the healthcare and bioscience industry. The financial services include equity investments (VC/PE), PIPE, FOF (Fund of Funds), securities investing, M&A and etc.